Integral Health Asset Management LLC Has $14.86 Million Stock Position in Tarsus Pharmaceuticals, Inc. $TARS

Integral Health Asset Management LLC grew its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 25.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 250,000 shares of the company’s stock after buying an additional 50,000 shares during the quarter. Tarsus Pharmaceuticals makes up 1.0% of Integral Health Asset Management LLC’s holdings, making the stock its 28th biggest holding. Integral Health Asset Management LLC’s holdings in Tarsus Pharmaceuticals were worth $14,858,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of TARS. TimesSquare Capital Management LLC bought a new position in shares of Tarsus Pharmaceuticals during the third quarter valued at $15,898,000. Jennison Associates LLC increased its stake in shares of Tarsus Pharmaceuticals by 5.5% in the third quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock valued at $154,790,000 after buying an additional 136,582 shares during the period. TFG Asset Management GP Ltd increased its stake in shares of Tarsus Pharmaceuticals by 40.1% in the second quarter. TFG Asset Management GP Ltd now owns 250,000 shares of the company’s stock valued at $10,128,000 after buying an additional 71,530 shares during the period. Capricorn Fund Managers Ltd bought a new position in shares of Tarsus Pharmaceuticals during the third quarter worth about $14,264,000. Finally, Jump Financial LLC raised its holdings in Tarsus Pharmaceuticals by 385.9% during the 2nd quarter. Jump Financial LLC now owns 237,117 shares of the company’s stock worth $9,606,000 after purchasing an additional 188,317 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors.

Insider Transactions at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 7,397 shares of the company’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total value of $592,499.70. Following the completion of the sale, the insider directly owned 38,958 shares of the company’s stock, valued at approximately $3,120,535.80. This represents a 15.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Bobak R. Azamian sold 6,000 shares of the stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the sale, the chief executive officer directly owned 857,991 shares of the company’s stock, valued at $70,792,837.41. The trade was a 0.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 8.97% of the stock is owned by company insiders.

Tarsus Pharmaceuticals Stock Down 0.3%

Shares of NASDAQ TARS opened at $67.96 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 3.82. Tarsus Pharmaceuticals, Inc. has a 1 year low of $38.51 and a 1 year high of $85.25. The stock has a market capitalization of $2.89 billion, a P/E ratio of -41.95 and a beta of 0.55. The company has a 50-day moving average price of $70.21 and a 200-day moving average price of $69.90.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The business had revenue of $151.67 million during the quarter, compared to the consensus estimate of $144.56 million. On average, equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TARS has been the topic of a number of analyst reports. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $68.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Barclays assumed coverage on Tarsus Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $100.00 price objective on the stock. Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Mizuho assumed coverage on Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They set an “outperform” rating and a $100.00 target price for the company. Finally, Guggenheim lifted their target price on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $91.83.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.